VantAI, a generative AI company specialized in programmable protein interactions, and Halda Therapeutics have announced a strategic research collaboration valued over $1 billion to accelerate proximity-based therapies in cancer and immunology. Leveraging VantAI’s Neo-1 foundation model and NeoLink proteomics platform, the partnership aims to identify novel target-effector pairs feeding into Halda’s RIPTAC drug discovery pipeline. This alliance harnesses AI-driven molecular generation and experimental data to develop selective therapies exploiting induced proximity mechanisms beyond traditional modalities.